NASDAQ:SBBP Strongbridge Biopharma Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Strongbridge Biopharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Today's Range$1.95▼$2.0650-Day Range$1.89▼$2.2952-Week Range$1.85▼$4.26Volume684,684 shsAverage Volume866,464 shsMarket Capitalization$135.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Receive SBBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SBBP Stock Forecast (MarketRank)Overall MarketRank™0.97 out of 5 starsMedical Sector1263rd out of 1,418 stocksPharmaceutical Preparations Industry624th out of 679 stocksAnalyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Strongbridge Biopharma. Previous Next 4.0 Community Rank Outperform VotesStrongbridge Biopharma has received 311 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStrongbridge Biopharma has received 206 “underperform” votes. (Add your “underperform” vote.)Community SentimentStrongbridge Biopharma has received 60.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote “Outperform” if you believe SBBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStrongbridge Biopharma does not currently pay a dividend.Dividend GrowthStrongbridge Biopharma does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Strongbridge Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Strongbridge Biopharma is held by insiders.Percentage Held by Institutions52.03% of the stock of Strongbridge Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Strongbridge Biopharma are expected to decrease in the coming year, from ($0.56) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Strongbridge Biopharma is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Strongbridge Biopharma is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStrongbridge Biopharma has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Strongbridge Biopharma (NASDAQ:SBBP)Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Read More SBBP Stock News HeadlinesSeptember 23, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.August 31, 2021 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisAugust 5, 2021 | finance.yahoo.comStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 2, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy StatementJuly 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021July 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in IssueJuly 28, 2021 | nasdaq.comStrongbridge Biopharma's (NASDAQ:SBBP) Stock Price Has Reduced 48% In The Past Three YearsJuly 27, 2021 | finance.yahoo.comStrongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseJuly 26, 2021 | msn.comBRIEF-Strongbridge Biopharma Plc, Unit, Avenue Venture Opportunities Fund Enter Amendment To A Term Loan AgreementJuly 15, 2021 | nasdaq.comStrongbridge Biopharma plc Ordinary Shares (SBBP)July 13, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & NerveJune 29, 2021 | markets.businessinsider.comTudor Capital Europe LLP : Form 8.3 - Strongbridge Biopharma PlcJune 3, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s SyndromeSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SBBP CUSIPN/A CIK1634432 Webwww.strongbridgebio.com Phone(610) 254-9200FaxN/AEmployees72Year FoundedN/ACompany Calendar Last Earnings8/05/2021Today6/24/2022Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45.08 million Net Margins-115.67% Pretax MarginN/A Return on Equity-66.82% Return on Assets-36.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.00 Quick Ratio2.95 Sales & Book Value Annual Sales$30.73 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book2.04Miscellaneous Outstanding Shares67,829,000Free FloatN/AMarket Cap$135.66 million OptionableOptionable Beta1.58 Strongbridge Biopharma Frequently Asked Questions How were Strongbridge Biopharma's earnings last quarter? Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%. View Strongbridge Biopharma's earnings history. Who are Strongbridge Biopharma's key executives? Strongbridge Biopharma's management team includes the following people: John H. Johnson, Chief Executive Officer & DirectorRichard S. Kollender, President & Chief Financial OfficerFredric Cohen, Chief Medical OfficerBrian Conner, Chief Compliance OfficerPeter J. Valentinsson, Senior Vice President-Global Technical Operations Who are some of Strongbridge Biopharma's key competitors? Some companies that are related to Strongbridge Biopharma include Janux Therapeutics (JANX), Eagle Pharmaceuticals (EGRX), IDEAYA Biosciences (IDYA), Tricida (TCDA), Stoke Therapeutics (STOK), Kinnate Biopharma (KNTE), Geron (GERN), 2seventy bio (TSVT), Celularity (CELU), Cara Therapeutics (CARA), Bicycle Therapeutics (BCYC), Pharming Group (PHAR), ANI Pharmaceuticals (ANIP), Calliditas Therapeutics AB (publ) (CALT) and Mersana Therapeutics (MRSN). View all of SBBP's competitors. What other stocks do shareholders of Strongbridge Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB). What is Strongbridge Biopharma's stock symbol? Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP." What is Strongbridge Biopharma's stock price today? One share of SBBP stock can currently be purchased for approximately $2.00. How much money does Strongbridge Biopharma make? Strongbridge Biopharma (NASDAQ:SBBP) has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45.08 million in net income (profit) each year or ($0.78) on an earnings per share basis. How many employees does Strongbridge Biopharma have? Strongbridge Biopharma employs 72 workers across the globe. How can I contact Strongbridge Biopharma? Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The official website for Strongbridge Biopharma is www.strongbridgebio.com. The biotechnology company can be reached via phone at (610) 254-9200 or via email at [email protected]. This page (NASDAQ:SBBP) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
